Mirum, Incyte say FDA approves Atebrioz for FOP patients
The FDA approved Atebrioz (zilurgisertib) tablets for adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The companies said the treatment will be available in the U.S. in October through Mirum Access Plus, and the agency issued Incyte a rare pediatric disease priority revie